Administrative Core
Administrative Core
批准号:
10931064
负责人:
Marina Y Konopleva
金额:
$17.74万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-09-01 至 2024-08-31
关键词:
AddressAdministratorAdvocateAwardBioinformaticsBiometryCancer CenterCancer Center Support GrantCaringCell TherapyClinicClinicalClinical TrialsCollaborationsCommunicationComplexConsultationsDataDecision MakingDevelopmentDoctor of MedicineElectronic MailEligibility DeterminationEnsureFox Chase Cancer CenterGrantInfrastructureInstitutionInterdisciplinary StudyLaboratoriesLeadershipMinorityMonitorNational Cancer InstituteOrganOutcomePathologyPatientsPoliciesPreparationPrognosisProgress ReportsProtocols documentationPublicationsQuality ControlRegulationReportingReproduction sporesResearchResearch ActivityResearch InfrastructureResearch PersonnelResearch Project GrantsSiteStem cell transplantStrategic PlanningSupervisionTexasTissuesTranslational ResearchUnited States National Institutes of HealthUniversitiesUniversity of Texas M D Anderson Cancer CenterWomanWorkcareerdata managementdata sharingdesignexperienceimprovedinterdisciplinary collaborationlecturesleukemiameetingsnovelprogramsquality assurancerecruitscreeningsuccesssymposiumtransplantation therapyweb site
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY (ADMINISTRATIVE CORE)
The Administrative Core provides essential support to the MD Anderson Cancer Center and Temple/Fox
Chase Cancer Center Leukemia SPORE PIs and investigators to maximize success. It is co-directed by Drs.
Hagop Kantarjian and Jean-Pierre Issa, who co-chair the Executive Committee and provide overall supervision
of five Projects, two additional Cores, Developmental Research (DRP) and Career Enhancement (CEP)
Programs, and scientific direction of the SPORE. The Core co-Directors rely on the extensive broad-based
scientific, research, and SPORE experience of the Internal and External Advisory Boards in critical decision-
making. Success of the complex interdisciplinary research in the SPORE depends on integration of diverse
leukemia research approaches. The Core will overcome barriers to interdisciplinary collaboration and data
sharing and will ensure a unified translational research effort. The SPORE is founded on planning, integration,
and translational research efforts supported by this Core. Its leadership and staff will be responsible for
monitoring/planning scientific activities; providing scientific direction; ensuring emphasis on translational
research; ensuring interdisciplinary and inter-SPORE integration with major leukemia programs within/outside
MD Anderson and other broad translational research activities; and providing optimal administrative and fiscal
management. Specific responsibilities of the Administrative Core are: Oversee and monitor all SPORE
activities; promote integration and communication among the SPORE-related clinical programs; monitor the
scientific integrity of all research projects, and grant awards; assure compliance with institutional,
governmental, and National Cancer Institute regulations; oversee the fiscal and budgetary activities of the
SPORE; coordinate data control quality assurance issues in conjunction with the Internal Advisory Board and
the Biostatistics, Data Management, and Bioinformatics Core (Core 3); coordinate activities associated with
clinical trials, including design of protocols, approval by regulatory bodies, implementation, and eligibility
screening and assignment of patients to different studies; provide oversight and support for Core 3 and the
Pathology and Tissue Core (Core 2); coordinate and manage meetings of the SPORE Executive Committee,
the Internal and External Advisory Boards, monthly investigator meetings, quarterly research meetings,
lectures, and symposia; administer the DRP and the CEP; coordinate interdisciplinary and inter-SPORE
interactions and exchanges/meetings with other Leukemia SPORE programs and investigators, and other
organ-site SPORE programs; administer the activities of the Patient Advocates; comply with, and improve
policies addressing recruitment and retention of women and minorities; organize seminars to bring to MD
Anderson consultants and speakers with expertise in various clinical and laboratory aspects of leukemia
research; maintain a Leukemia SPORE website focused on issues in leukemia translational research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the novel cancer testis antigen HSPA1L as immunotherapeutic target in AML
-
批准号:10625516
-
项目类别:
-
资助金额:$18.56万
-
财政年份:2022
-
负责人:Marina Y Konopleva
-
依托单位:
Defining the novel cancer testis antigen HSPA1L as immunotherapeutic target in AML
-
批准号:10433726
-
项目类别:
-
资助金额:$22.72万
-
财政年份:2022
-
负责人:Marina Y Konopleva
-
依托单位:
Inhibition of Bcl-xL by Targeted Degradation
-
批准号:10737840
-
项目类别:
-
资助金额:$7.28万
-
财政年份:2020
-
负责人:Marina Y Konopleva
-
依托单位:
Chaperone-Mediated Protein Degradation of Bcl-xL and Bcl-2
-
批准号:10599452
-
项目类别:
-
资助金额:$4.7万
-
财政年份:2020
-
负责人:Marina Y Konopleva
-
依托单位:
Inhibition of Bcl-xL by Targeted Degradation
-
批准号:10378075
-
项目类别:
-
资助金额:$49.56万
-
财政年份:2020
-
负责人:Marina Y Konopleva
-
依托单位:
Inhibition of Bcl-xL by Targeted Degradation
-
批准号:10133018
-
项目类别:
-
资助金额:$50.57万
-
财政年份:2020
-
负责人:Marina Y Konopleva
-
依托单位:
Inhibition of Bcl-xL by Targeted Degradation
-
批准号:10644990
-
项目类别:
-
资助金额:$49.56万
-
财政年份:2020
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen
-
批准号:10415997
-
项目类别:
-
资助金额:$9.6万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen
-
批准号:10654631
-
项目类别:
-
资助金额:$4.55万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting mitochondrial complex I in acute lymphoblastic leukemia
-
批准号:9815737
-
项目类别:
-
资助金额:$58.75万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen
-
批准号:10174866
-
项目类别:
-
资助金额:$37.48万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting mitochondrial complex I in acute lymphoblastic leukemia
-
批准号:10437742
-
项目类别:
-
资助金额:$7.0万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen
-
批准号:10745877
-
项目类别:
-
资助金额:$27.09万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting mitochondrial complex I in acute lymphoblastic leukemia
-
批准号:10170323
-
项目类别:
-
资助金额:$61.87万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting mitochondrial complex I in acute lymphoblastic leukemia
-
批准号:10745872
-
项目类别:
-
资助金额:$28.74万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Targeting mitochondrial complex I in acute lymphoblastic leukemia
-
批准号:10654665
-
项目类别:
-
资助金额:$46.91万
-
财政年份:2019
-
负责人:Marina Y Konopleva
-
依托单位:
Therapeutic targeting of glutamine metabolism in MDS
-
批准号:9117917
-
项目类别:
-
资助金额:$50.69万
-
财政年份:2016
-
负责人:Marina Y Konopleva
-
依托单位:
Therapeutic targeting of glutamine metabolism in MDS
-
批准号:9901359
-
项目类别:
-
资助金额:$48.15万
-
财政年份:2016
-
负责人:Marina Y Konopleva
-
依托单位:
Therapeutic targeting of glutamine metabolism in MDS
-
批准号:9250735
-
项目类别:
-
资助金额:$47.48万
-
财政年份:2016
-
负责人:Marina Y Konopleva
-
依托单位:
Hypoxia-Selective Kinase Inhibitors for Leukemia Therapy
-
批准号:8527296
-
项目类别:
-
资助金额:$15.73万
-
财政年份:2013
-
负责人:Marina Y Konopleva
-
依托单位:
海外基金